News

Discover Ovid Therapeutics' Latest Innovations for Epilepsy Care

Discover Ovid Therapeutics' Latest Innovations for Epilepsy Care

Ovid Therapeutics: Pioneering Innovations in Epilepsy Treatment

Ovid Therapeutics Inc. (NASDAQ: OVID) is making significant strides in the biopharmaceutical space, focusing on therapeutic solutions for brain conditions that urgently need attention. This company takes on that challenge with a clear mission: to develop innovative medicines aimed at conditions like epilepsy, where existing treatments fall short.

Upcoming Event to Highlight Biomarkers in Drug Development

On a notable day soon, Ovid will host an exciting investor and media event focused on the critical role of biomarkers in epilepsy. This event will deep dive into how these biomarkers are strategically utilized in the development of OV329, a promising candidate in Ovid's clinical pipeline. With industry-leading expert Dr. Alexander Rotenberg, who brings extensive expertise from Boston Children’s Hospital and Harvard Medical School, attendees will gain valuable insights into the evolving landscape of epilepsy treatment.

Exploring Advanced Techniques in Clinical Development

The event's discussions will showcase how advanced imaging and radiological techniques enable the identification of critical biological signals during the early stages of clinical trials. These innovative approaches support evidence-driven strategies in drug development, potentially leading to improved patient outcomes.

OV329: A New Hope for Patients with Epilepsy

Currently, about 40% of individuals suffering from epilepsy face ongoing seizures despite available treatments. Here’s where OV329, a next-generation GABA-AT inhibitor, steps in. Designed with a unique mechanism, OV329 aims to provide an innovative solution for those who have not found relief with conventional therapies. By restoring optimal levels of GABA, OV329 seeks to reduce seizures while exhibiting a better safety and tolerability profile compared to first-generation medications.

Understanding the Clinical Journey of OV329

Ovid is actively completing a Phase 1 study of OV329, which is designed to evaluate the drug's safety, tolerability, and impact on various pharmacodynamic biomarkers. This focused approach underscores the company's dedication to ensuring that their treatments meet the vital needs of patients.

Registration and Participation Details

For those interested in attending this pivotal event, Ovid encourages participation either in-person at their New York headquarters or via a live webcast. You can easily register for the event to keep up with the latest developments in epilepsy treatment strategies.

About Ovid Therapeutics

Ovid Therapeutics stands at the forefront of biopharmaceutical innovation, dedicated to developing small molecule medicines that address significant unmet needs in brain health. By leveraging cutting-edge research, Ovid aims to advance therapeutic solutions not just for epilepsy, but also for a range of neurological and neuropsychiatric disorders.

The company’s promising portfolio includes compounds like OV329, tailored for treatment-resistant seizures, and other candidates designed to activate the KCC2 transporter, showcasing Ovid’s commitment to multifaceted approaches in the quest for effective therapies.

If you wish to learn more about Ovid Therapeutics and their research initiatives, visit their official website.

Frequently Asked Questions

What is the purpose of the event hosted by Ovid Therapeutics?

The event aims to educate attendees on the use of biomarkers in epilepsy and provide insights into Ovid's OV329 clinical development program.

Who is the keynote speaker at the event?

Dr. Alexander Rotenberg, a renowned pediatric neurologist, will share his expertise on the application of biomarkers in epilepsy treatments.

What is OV329?

OV329 is a next-generation GABA-AT inhibitor aimed at treating individuals with treatment-resistant seizures for potentially better outcomes than traditional therapies.

Where is Ovid Therapeutics located?

Ovid Therapeutics is based in New York, dedicated to developing innovative treatments for neurological conditions.

How can I register for the event?

Interested participants can register for the event through the registration link provided by Ovid Therapeutics.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 38

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 179

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 21

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 53

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
OFRM Recall Leaves Investors Facing Hard Questions

Updated Category News Views 60

Nothing wrecks a young consumer brand’s glow faster than a recall involving toddlers, and Once Upon A Farm has just learned that lesson in the ugliest possible way. On November 2, 2026, shares of NYSE:OFRM fell 37% to close at $9.44. That left the stock roughly 47% below its $18 IPO price. Those are not the garden-variety bruises of a weak quarter. That is the market...

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 156

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Gildan Lawsuit Puts Revenue Controls Under a Harsh Light

Updated Category News Views 61

Receivables have a nasty way of becoming everybody’s problem once the story cracks. Gildan Activewear is staring at that uncomfortable reality after a securities fraud class action was filed on behalf of investors who bought or acquired shares between February 19, 2025 and June 15, 2026. The case, Cortez v. Gildan Activewear Inc., is pending in the U.S. District Court...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 80

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 113

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 87

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading

Top 5 Most Recently Viewed Articles

Gen Z's Evolving College Search: The Impact of Politics

Updated Category News Views 205

Understanding Gen Z's College Decisions In recent times, higher education choices have become a significant reflection of societal shifts, especially concerning political climates. A new report from an education company highlights how politics influence college decisions among Gen Z students. This demographic, characterized as more conscious of political environments,...

Continue Reading
LiveWire and KYMCO Unveil Electric Maxi-Scooter Plans

Updated Category News Views 46

LiveWire and KYMCO Strengthen Partnership LiveWire, a prominent figure in the electric motorcycle industry, has exciting news to share. In collaboration with KYMCO, a highly regarded powersports manufacturer, the two companies are working to amplify their strategic alliance. This partnership focuses on introducing an electric maxi-scooter tailored specifically for the...

Continue Reading
Rudholm Group's Compliance Portal: Regulatory Game Changer or Just Noise?

Updated Category News Views 180

Rudholm Group just unveiled its new Compliance Portal on February 18, 2026, aiming to tackle the labyrinth of ever-evolving regulations in the apparel sector. You know how it is—every corner of this industry is drowning in red tape, and brands are gasping for air trying to keep up with local laws that change faster than a fashion trend. The CEO, Dennis Lau, stated they...

Continue Reading
Teva's Upcoming Conference Call for Q4 Financial Results

Updated Category News Views 74

Teva's Upcoming Conference Call for Q4 Financial Results TEL AVIV, Israel — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced an important event for investors and stakeholders. The company plans to release its fourth quarter 2025 financial results on a specific date. Following the release, Teva will host a conference call and a live webcast to...

Continue Reading
Understanding the Recent Decline of Moderna's Stock and Future Prospects

Updated Category News Views 178

Moderna's Stock Takes a Dive: Key Factors Explained Moderna Inc (NASDAQ: MRNA) has faced a significant drop in its stock value recently, prompting investors to seek clarity on the reasons behind this decline. The company has been in the news with some critical developments that have overshadowed its achievements in the medical field. Recent Clinical Setbacks The primary...

Continue Reading